Article Cited by others

ORIGINAL ARTICLE

The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis

Luo Yong, Gou Xin, Huang Peng, Mou Chan

Year : 2014| Volume: 16| Issue : 3 | Page no: 487-492

   This article has been cited by
 
1 Biomarkers for detecting prostate cancer
Junhai Jia,Yue Sun,Jingjie Ren,Muyang Li,Jiancheng Wang,Haiyang Li
Medicine. 2019; 98(30): e16517
[Pubmed]  [Google Scholar] [DOI]
2 Forecasting, uncertainty and risk; perspectives on clinical decision-making in preventive and curative medicine
Spyros Makridakis,Richard Kirkham,Ann Wakefield,Maria Papadaki,Joanne Kirkham,Lisa Long
International Journal of Forecasting. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Urinary extracellular vesicle biomarkers in urological cancers: From discovery towards clinical implementation
Bert Dhondt,Jan Van Deun,Silke Vermaerke,Ario de Marco,Nicolaas Lumen,Olivier De Wever,An Hendrix
The International Journal of Biochemistry & Cell Biology. 2018; 99: 236
[Pubmed]  [Google Scholar] [DOI]
4 Long non-coding RNAs in prostate cancer: Biological and clinical implications
Rajdeep Das,Felix Y. Feng,Luke A. Selth
Molecular and Cellular Endocrinology. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 New biomarkers for diagnosis and prognosis of localized prostate cancer
Dimitry A. Chistiakov,Veronika A. Myasoedova,Andrey V. Grechko,Alexandra A. Melnichenko,Alexander N. Orekhov
Seminars in Cancer Biology. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5a-reductase inhibitors
Vincent Fradet,Paul Toren,Molière Nguile-Makao,Michele Lodde,Jérome Lévesque,Caroline Léger,André Caron,Alain Bergeron,Tal Ben-Zvi,Louis Lacombe,Frédéric Pouliot,Rabi Tiguert,Thierry Dujardin,Yves Fradet
BJU International. 2017;
[Pubmed]  [Google Scholar] [DOI]
7 Urinary biomarkers in prostate cancer detection and monitoring progression
Duojia Wu,Jie Ni,Julia Beretov,Paul Cozzi,Mark Willcox,Valerie Wasinger,Bradley Walsh,Peter Graham,Yong Li
Critical Reviews in Oncology/Hematology. 2017; 118: 15
[Pubmed]  [Google Scholar] [DOI]
8 Low-risk Prostate Cancer: Identification, Management, and Outcomes
Marco Moschini,Peter R. Carroll,Scott E. Eggener,Jonathan I. Epstein,Markus Graefen,Rodolfo Montironi,Christopher Parker
European Urology. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance
J J Tosoian,H D Patel,M Mamawala,P Landis,S Wolf,D J Elliott,J I Epstein,H B Carter,A E Ross,L J Sokoll,C P Pavlovich
Prostate Cancer and Prostatic Diseases. 2017;
[Pubmed]  [Google Scholar] [DOI]
10 Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy
Vito Cucchiara,Joy Yang,Vincenzo Mirone,Allen Gao,Michael Rosenfeld,Christopher Evans
Cancers. 2017; 9(1): 9
[Pubmed]  [Google Scholar] [DOI]
11 Biomarkers in localized prostate cancer
Matteo Ferro,Carlo Buonerba,Daniela Terracciano,Giuseppe Lucarelli,Vincenzo Cosimato,Danilo Bottero,Victor M Deliu,Pasquale Ditonno,Sisto Perdonà,Riccardo Autorino,Ioman Coman,Sabino De Placido,Giuseppe Di Lorenzo,Ottavio De Cobelli
Future Oncology. 2016; 12(3): 399
[Pubmed]  [Google Scholar] [DOI]
12 Urinary Biomarkers for Prostate Cancer
Jeffrey J. Tosoian,Ashley E. Ross,Lori J. Sokoll,Alan W. Partin,Christian P. Pavlovich
Urologic Clinics of North America. 2016; 43(1): 17
[Pubmed]  [Google Scholar] [DOI]
13 The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements
Pierre-Olivier Gaudreau,John Stagg,Denis Soulières,Fred Saad
Biomarkers in Cancer. 2016; 8s2: BIC.S31802
[Pubmed]  [Google Scholar] [DOI]
14 Recent progress and perspectives on prostate cancer biomarkers
Shingo Hatakeyama,Tohru Yoneyama,Yuki Tobisawa,Chikara Ohyama
International Journal of Clinical Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
15 Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients
Ahva Shahabi,Juan Pablo Lewinger,Jie Ren,Craig April,Andy E. Sherrod,Joseph G. Hacia,Siamak Daneshmand,Inderbir Gill,Jacek K. Pinski,Jian-Bing Fan,Mariana C. Stern
The Prostate. 2016;
[Pubmed]  [Google Scholar] [DOI]
16 Urinary biomarkers for prostate cancer
John T. Wei
Current Opinion in Urology. 2015; 25(1): 77
[Pubmed]  [Google Scholar] [DOI]
17 PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience
Roberta Merola,Luigi Tomao,Anna Antenucci,Isabella Sperduti,Steno Sentinelli,Serena Masi,Chiara Mandoj,Giulia Orlandi,Rocco Papalia,Salvatore Guaglianone,Manuela Costantini,Giuseppe Cusumano,Giovanni Cigliana,Paolo Ascenzi,Michele Gallucci,Laura Conti
Journal of Experimental & Clinical Cancer Research. 2015; 34(1)
[Pubmed]  [Google Scholar] [DOI]
18 Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers
Todd Morgan,Ganesh Palapattu,John Wei
Current Urology Reports. 2015; 16(9)
[Pubmed]  [Google Scholar] [DOI]
19 The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Amanda Nicholson,James Mahon,Angela Boland,Sophie Beale,Kerry Dwan,Nigel Fleeman,Juliet Hockenhull,Yenal Dundar
Health Technology Assessment. 2015; 19(87): 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article